Esrar
Synopsis
This chapter examines the general characteristics, history, pharmacological, and forensic toxicological dimensions of cannabis (Cannabis). Containing over 545 compounds and 104 phytocannabinoids across subspecies including Cannabis sativa, indica, and ruderalis, the plant's primary psychoactive constituent is Delta-9-tetrahydrocannabinol (THC), whereas cannabidiol (CBD) serves as the main non-psychoactive component. Cannabinoids exert their effects via G-protein-coupled CB1 and CB2 receptors located in the central and peripheral nervous systems. Endogenous cannabinoids, such as anandamide (AEA) and 2-AG, act as modulators in physiological processes including pain, appetite, and memory. Cannabis induces euphoria, relaxation, and perceptual alterations alongside impairments in short-term memory and motor coordination. Therapeutically, medications like nabiximols, dronabinol, nabilone, and plant-derived cannabidiol (Epidiolex®) have gained regulatory approval for managing multiple sclerosis-related spasticity, neuropathic pain, chemotherapy-induced nausea/vomiting, and specific epileptic conditions. Toxicological evaluations rely on chromatographic methods such as GC-MS and LC-MS alongside immunoassay screenings (EMIT, ELISA) to detect THC and its primary metabolites (THC-OH, THC-COOH) in biological matrices including urine, blood, saliva, and hair. Meanwhile, rising THC concentrations and evolving legal frameworks diminish perceived risks, reinforcing the necessity of strict forensic monitoring for public health.
References
ElSohly M, Gul W. Constituents of Cannabis Sativa. Hanbook of Cannabis. 1st ed. Oxford: Oxford University Press; 2014. p. 3–22.
Hillig KW. Genetic evidence for speciation in Cannabis (Cannabaceae). Genetic Resources and Crop Evolution. 2005;52(2): 161–180. doi:10.1007/s10722-003-4452-y
Russo E. The Pharmacological History of Cannabis. Hanbook of Cannabis. 1st ed. Oxford: Oxford University Press; 2014. p. 23–43.
Crocq MA. History of cannabis and the endocannabinoid system. Dialogues in Clinical Neuroscience. 2020;22(3): 223–228. doi:10.31887/DCNS.2020.22.3/MCROCQ
Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1960;86: 1646–1647.
Pisanti S, Bifulco M. Modern History of Medical Cannabis: From Widespread Use to Prohibitionism and Back. Trends in Pharmacological Sciences. Elsevier Ltd; 2017;38(3): 195–198. doi:10.1016/j.tips.2016.12.002
Ulugöl A. Kannabis Bitkisi ve Kannabinoidlere Giriş. Turkiye Klinikleri J Pharmacol-Special Topics. 2018;6(1): 1–5.
Akgür SA, Aydoğdu M. Cannabis Use in Turkey. Turkiye Klinikleri J Pharmacol-Special Topics. 2018;6(1): 57–61.
Alharbi YN. Current legal status of medical marijuana and cannabidiol in the United States. Epilepsy and Behavior. Elsevier Inc.; 2020;112: 107452. doi:10.1016/j.yebeh.2020.107452
Topuz RD. Kannabi̇noi̇dleri̇n farmakoloji̇si̇. Pharmacol-Special Topics. 2018;6(1): 6–14.
Grotenhermen F. Pharmacokinetics and the pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4): 328–350. doi:10.1111/bcp.13710
Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review. Drug Metabolism Reviews. 2014;46(1): 86–95. doi:10.3109/03602532.2013.849268
Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. British Journal of Clinical Pharmacology. 2018;84(11): 2477–2482. doi:10.1111/bcp.13710
Pertwee RG. Pharmacological and therapeutic targets for Δ9- tetrahydrocannabinol and cannabidiol. Euphytica. 2004;140(1–2): 73–82. doi:10.1007/s10681-004-4756-9
Pertwee R. Receptors and Channels Targeted by Synthetic Cannabinoid Receptor Agonists and Antagonists. Current Medicinal Chemistry. 2010;17(14): 1360–1381. doi:10.2174/092986710790980050
Amin R, Ali D. Pharmacology of medical cannabis. Adv Exp Med Biol. 2019;1162: 151–165.
Gündüz Ö. Endokannabinoid sistem. Türkiye Klinikleri Farmakoloji Özel Konular. 2018;6(1): 15–24.
Russo EB. Beyond Cannabis: Plants and the Endocannabinoid System. Trends in Pharmacological Sciences. Elsevier Ltd; 2016;37(7): 594–605. doi:10.1016/j.tips.2016.04.005
Ulugöl A. The endocannabinoid system as a potential therapeutic target for pain modulation. Balkan Medical Journal. 2014;31(2): 115–120. doi:10.5152/balkanmedj.2014.13103
Topuz RD, Gündüz Ö, Karadağ ÇH, et al. Non-opioid Analgesics and the Endocannabinoid System. Balkan medical journal. 2020;37(6): 309–315. doi:10.4274/balkanmedj.galenos.2020.2020.6.66
Ashton CH. Pharmacology and effects of cannabis: A brief review. British Journal of Psychiatry. 2001;178(FEB.): 101–106. doi:10.1192/bjp.178.2.101
Hall W, Degenhardt L, Lynskey M. The health and psychological effects of cannabis use.. 2nd ed. Canberra: University of New South Wales; 2001.
Karch S. Pharmacokinetics and Pharmacodynamics of abused Drugs. CRC press; 2008.
Hart CL, Ward AS, Haney M, et al. Comparison of smoked marijuana and oral Δ9-tetrahydrocannabinol in humans. Psychopharmacology. 2002;164(4): 407–415. doi:10.1007/s00213-002-1231-y
Akgür SA. Esrar ve Kannabinoidler. In: Akgür SA, Coşkunol H (eds.) Bağımlılık Yapıcı Maddeler ve Toksikolojisi. Ege Üniversitesi Madde Bağımlılığı, Toksikoloji ve İlaç Bilimleri Enstitüsü Yayınları No:3; 2014. p. 93–107.
Notcutt W, Clarke E. Cannabinoids in Clinical Practice: A UK Perspective. Hanbook of Cannabis. 1st ed. Oxford: Oxford University Press; 2014. p. 415–432.
Yassa HA, Dawood AEWA, Shehata MM, et al. Subchronic toxicity of cannabis leaves on male albino rats. Human and Experimental Toxicology. 2010;29(1): 37–47. doi:10.1177/0960327109354312
Ulugöl A. Kannabinoidlerin klinikte kullanılışı ve terapötik hedefler. Türkiye Klinikleri Farmakoloji Özel Konular. 2018;6(1): 42–50.
Pryce G, Baker D. Cannabis and Multiple Sclerosis. In: Pertwee R (ed.) Hanbook of Cannabis. 1st ed. Oxford: Oxford University Press; 2014. p. 487–501.
Robson PJ. Therapeutic potential of cannabinoid medicines. Drug Testing and Analysis. 2014;6(1–2): 24–30. doi:10.1002/dta.1529
Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Multiple Sclerosis Journal. 2012;18(2): 219–228. doi:10.1177/1352458511419700
Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology. 2011;18(9): 1122–1131. doi:10.1111/j.1468-1331.2010.03328.x
Nielsen S, Germanos R, Weier M, et al. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Current Neurology and Neuroscience Reports. Current Neurology and Neuroscience Reports; 2018;18(2). doi:10.1007/s11910-018-0814-x
Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6): 812–819.
Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain. Journal of Pain and Symptom Management. Elsevier Inc; 2010;39(2): 167–179. doi:10.1016/j.jpainsymman.2009.06.008
Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology. 2006;45(1): 50–52. doi:10.1093/rheumatology/kei183
Rock E, Sticht M, Parker L. Effect of Phytocannabinoids on Nausea and Vomiting. In: Pertwee R (ed.) Hanbook of Cannabis. 1st ed. Oxford: University Press; 2014. p. 436–454.
Duran M, Pérez E, Abanades S, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. British Journal of Clinical Pharmacology. 2010;70(5): 656–663. doi:10.1111/j.1365-2125.2010.03743.x
Karadağ Ç. Kannabinoidlerin santral sinir sistemine etkileri. Türkiye Klinikleri Farmakoloji Özel Konular. 2018;6(1): 25–34.
Cristino L, Di Marzo V. Established and Emerging Concepts of Cannabinoid Action on Food Intake and their Potential Application to the Treatment of Anorexia and Cachexia. In: Pertwee R (ed.) Hanbook of Cannabis. 1st ed. Oxford: Oxford University Press; 2014. p. 455–472.
Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. The Lancet Neurology. Elsevier Ltd; 2016;15(3): 270–278. doi:10.1016/S1474-4422(15)00379-8
Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry. 2012;2(October 2011). doi:10.1038/tp.2012.15
Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA - Journal of the American Medical Association. 2015;313(24): 2456–2473. doi:10.1001/jama.2015.6358
Fernández-Ruiz J, Lago E de, Gómez-Ruiz M, et al. Neurodegenerative Disorders Other Than Multiple Sclerosis. In: Pertwee R (ed.) Hanbook of Cannabis. 1st ed. Oxford: Oxford University Press; 2014. p. 505–525.
Huestis MA. Pharmacokinetics and Metabolism of the Plant Cannabinoids, ∆9-Tetrahydrocannabinol, Cannabidiol and Cannabinol. In: Pertwee RG (ed.) Cannabinoids. Springer; 2005. p. 657–690.
Cone EJ, Bigelow GE, Herrmann ES, et al. Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results. Journal of Analytical Toxicology. 2015;39(1): 1–12. doi:10.1093/jat/bku116
Özşeker PE. Kannabinoidlerin Toksikolojik Analizi. i J Pharmacol-Special Topics. 2018;6(1): 74–77.
United Nations Office on Drugs and Crime (UNODC). World Drug Report 2017. [Online] https://www.unodc.org/wdr2017/field/Booklet_1_EXSUM.pdf
Duman M. Kannabise Pasif Maruziyet. Türkiye Klinikleri Farmakoloji Özel Sayısı. 2018;6(1): 68–73.
Özşeker P. Kannabinoidlerin Toksikolojik Analizi. Turkiye Klinikleri J Pharmacol-Special Topics. 2018;6(1): 74–77.
Goullé J-P, Saussereau E, Lacroix C. Delta-9-tetrahydrocannabinol pharmacokinetics. Ann Pharm Fr. 2008;66(4): 232–244.
Huestis M a. Human Cannabinoid Pharmacokinetics. Chemisty & Biodiversity. 2007;4(8): 1770–1804. doi:10.1002/cbdv.200790152.Human
Aydoğdu M, Akgür SA. Urine drug-testing tampering approaches : Turkish probationers. Medicine, Science and the Law. 2020; 1–8. doi:10.1177/0025802420956453
Herrman E, Cone E, Mitchell J, et al. Non-Smoker Exposure to Secondhand Cannabis Smoke II: Effect of Room Ventilation on the Physiological, Subjective, and Behavioral/Cognitive Effects. Drug Alcohol Depend. 2015;1(151): 194–202. doi:10.1016/j.drugalcdep.2015.03.019.Non-Smoker
Bostancı Demirci H, Acar S, Akgür SA. Kannabis Yasal, Ya Sonra…. The Bulletin of Legal Medicine. 2020;25(1): 51–58. doi:10.17986/blm.2020.v25i1.1366
Aldemir E, Döğer R, Aydoğdu M, et al. Cannabis, medical use and related policies reflections on society. Klinik Psikiyatri. 2019; 8–11. doi:DOI: 1 0.5505/kpd.201 9.46547 Kannabis,
Tubim. Turkey Drug Report 2017. [Online] 2017. http://www.narkotik.pol.tr/TUBIM/Documents/TURKIYE UYUSTURUCU RAPORU 2017.pdf
Parker H, Williams L, Aldridge J. The normalisation of ‘sensible’ recreational drug use: Further evidence from the North West Longitudinal Study. Drugs and Popular Culture: Drugs, Media and Identity in Contemporary Society. 2002;36(4): 74–95. doi:10.4324/9781843926016